Abstracts Archive

Nodal T Follicular Helper Lymphomas (nTFHL) are a recently defined category of mature T-cell neoplasms, which includes the prototypic angioimmunoblastic-type. Here, we present two cases, illustrating hallmark diagnostic features and key management issues. In Case 1, a 43-year-old female presented wi...

Background: ALK-positive anaplastic large-cell lymphoma (ALCL) usually carries a favorable prognosis in young adults. However, refractory or multiply relapsed disease remains a major therapeutic challenge. Data supporting sequential use of next-generation ALK inhibitors in systemic ALCL are limited...

Introduction: Although the proportion of T-cell lymphoma(TCL) patients originated from clonal hematopoiesis of indeterminate potential (CHIP) in hematopoietic stem cells, clinical and prognostic significance of CHIP in lymphoma is not systemically analyzed yet. This study aimed to evaluate the ...

IntroductionAnti-PD1 immunotherapy has shown encouraging albeit modest efficacy in relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) and NK/T-cell lymphoma (NKTL), achieving response rates of approximately 30% and 60%, respectively. Recent studies suggest that PARP inhibitors in tandem with ...

Introduction:Mature T-cell lymphomas, including aggressive nodal PTCL, advanced CTCL, and extranodal cytotoxic lymphomas, often have poor outcomes. Cytogenetic abnormalities are common, but their prognostic relevance remains unclear. We evaluated the impact of karyotype (KT) abnormalities, including...

Introduction:T-cell lymphomas (TCL) are a heterogenous group of aggressive lymphoid malignancies associated with limited therapeutic options and poor patient outcomes. Real-world barriers to treatment access remain poorly described, yet understanding these is vital for improving care equity.Objectiv...

Background Peripheral T-cell lymphomas (PTCLs) are heterogeneous neoplasms necessitating accurate sub-classification and molecular profiling for prognosis. Rare TP53-mutated TFH lymphomas are therapeutically challenging and often chemoresistant.  Case Presentation A 49-year-old man presented No...

IntroductionWith improved survival in acute myeloid leukemia (AML), second primary malignancies (SPMs) have emerged as significant long-term complications. Unlike relapse, SPMs are distinct malignancies arising from a different clonal origin.The occurrence of T-cell lymphoblastic lymphoma (T-LBL) fo...

IntroductionAngioimmunoblastic T-cell lymphoma (AITL) is a rare, systemic subtype of peripheral T-cell lymphoma characterized by profound immune dysregulation. Its ability to mimic infectious diseases, creates diagnostic challenges that delay treatment, particularly in tuberculosis endemic regions l...

Peripheral T-cell lymphomas are a group of heterogeneous lymphomas arising from mature T-cells. While diverse, these lymphomas often present at advanced stages and carry a poor prognosis. This study aimed to utilize a machine learning model to identify variables most associated with OS using compreh...

A 40-year-old previously healthy woman presented with rapidly progressive altered mental status, respiratory failure, pancytopenia and hemophagocytic lymphohistiocytosis (HLH) requiring ICU admission. Initial laboratory evaluation demonstrated a ferritin of 40,000 µg/L, fibrinogen 81 mg/dL, LDH 2,1...

A healthy 70-year-old man presented to medical attention after noticing a progressively enlarging right neck mass over several weeks, followed by the appearance of a similar mass on the left side. PET-CT revealed extensive FDG-avid nodal disease with bilateral cervical conglomerate involving bilate...

Introduction: The real-world treatment patterns and prognosis of patients with R/R mature T-cell and natural killer-cell lymphoma (MTNKL) in this new treatment era remains unclear. Objectives: We elucidated second-line (2L) therapy outcomes and treatment patterns for R/R MTNKL.Methods: This mul...

Introduction: Sézary syndrome (SS) is a rare, aggressive leukemic cutaneous T-cell lymphoma with historically poorer outcomes in Black patients.Objective: To evaluate racial and sex-based survival disparities in SS.Methods: 75 SS cases at Moffitt Cancer Center (MCC, 2015–2025) and ...

Introduction: Racial disparities in cutaneous T-cell lymphoma (CTCL) outcomes persist, with Black patients experiencing higher mortality. While novel agents like mogamulizumab and brentuximab vedotin improve survival, it remains unclear if differential access to these therapies contributes to outco...

Mogamulizumab is approved in the United States (US) for the treatment of adults with relapsed/refractory mycosis fungoides/Sézary syndrome (MF/SS) following ≥1 prior systemic treatment. This retrospective, observational cohort study used ConcertAI electronic medical records to investigate effecti...

Introduction: T-cell lymphomas (TCL) are highly aggressive with poor prognosis and limited treatment options. Epigenetic drugs such as the histone deacetylase inhibitor romidepsin and the DNA methyltransferase inhibitor azacytidine (Romi+AZA) synergize to reprogram tumor gene expression and impact ...

IntroductionAngioimmunoblastic T-cell lymphoma (AITL) is a rare, systemic subtype of peripheral T-cell lymphoma characterized by profound immune dysregulation. Its ability to mimic infectious diseases, creates diagnostic challenges that delay treatment, particularly in tuberculosis endemic regions l...

Introduction: Adult T-cell leukemia/lymphoma (ATLL) is a rare, aggressive T-cell neoplasm linked to chronic HTLV-1 infection. In non-endemic regions like the U.S., affected patients are primarily of Afro-Caribbean and Hispanic descent. Real-world data on treatment outcomes remain limited.Methods:&nb...

Background:North American Adult T-cell leukemia/lymphoma (NA-ATLL) is an aggressive HTLV-1–associated malignancy with median survival of less than one year. Interferon-alpha/Zidovudine in combination with other chemotherapy regimens showed efficacy in acute and chronic subtypes of ATLL. Our group ...

Introduction: Mogamulizumab, a CC chemokine receptor 4 (CCR4)-targeting antibody, is approved for relapsed/refractory mycosis fungoides/Sézary syndrome (MF/SS) following ≥1 systemic therapy. In a Phase 2 trial assessing a novel 2.0 mg/kg every-4-week dosing regimen (NCT04745234), immunologic and ...

Immune checkpoint inhibitors (ICIs) have been associated with paradoxical phenomena such as tumor pseudoprogression and hyperprogressive disease. This systematic literature review summarizes available reports of cutaneous T-cell lymphomas (CTCL) developing (de novo) or accelerating (pre-existing) du...

Background:Patients who progress with Cutaneous T-Cell Lymphoma (CTCL) often experience a life marred by pruritus and chronic skin involvement which negatively impacts their quality of life (QoL). In this study, we described racial and clinical disparities in patterns of care in CTCL in a single cen...

Introduction: Extranodal NK/T-cell lymphoma (ENKTL), nasal type, is typically treated with chemoradiotherapy but often causes significant toxicity. PD-1 inhibitors, pembrolizumab and tislelizumab, have shown efficacy in relapsed or refractory ENKTL, although responses may vary with the tumor microen...

IntroductionCutaneous T-Cell Lymphoma (CTCL) encompasses a heterogeneous group of malignancies, including Mycosis Fungoides (MF) and Sezary Syndrome (SS). Interferon alpha (IFN-α) has been a standard treatment for CTCL since 1984; however, data on pegylated interferons remain limited. This study ai...

A 50-year-old male presented with pruritus, generalized lymphadenopathy, thrombocytopenia, and fatigue. PET-CT demonstrated bilateral cervical, axillary, mediastinal, abdominal, and retroperitoneal lymphadenopathy, as well as splenomegaly, hepatomegaly, and diffuse splenic involvement. Excisional ly...

Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare CD30-positive T-cell lymphoproliferative disorder (TCLPD) that can present diagnostic and management challenges, particularly when overlapping with other CD30+ entities such as lymphomatoid papulosis (LyP) and mycosis fungoides (MF...

IntroductionAngioimmunoblastic T-cell lymphoma (AITL) is a rare, systemic subtype of peripheral T-cell lymphoma characterized by profound immune dysregulation. Its ability to mimic infectious diseases, creates diagnostic challenges that delay treatment, particularly in tuberculosis endemic regions l...

DR-01 is a non-fucosylated human IgG antibody targeting CD94, expressed on terminal effector CD8+T cells, γδT cells, and NK cells leading to depletion of CD94-expressing malignant cells by antibody-dependent cellular cytotoxicity. Patients with relapsed/refractory (R/R) cytotoxic T cell lymphomas ...